Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step Towards Personalized Therapy

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2019.04.012
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Inadequate Vancomycin Therapy in Term and Preterm Neonates: A Retrospective Analysis of Trough Serum Concentrations in Relation to Minimal Inhibitory Concentrations

BMC Pediatrics
Child HealthPediatricsPerinatology
2014English

Experience in the Use of Secukinumab in a Patient With Severe Palmoplantar Psoriasis

Klinicheskaya Dermatologiya i Venerologiya
DermatologyInfectious Diseases
2018English

Integrating Omics for a Better Understanding of Inflammatory Bowel Disease: A Step Towards Personalized Medicine

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

Targeted Therapy in Oncology: A Key Player in the Move Towards Personalized Medicine

Journal of Developing Drugs
2012English

Therapy Response Was Not Altered by HLA-Cw6 Status in Psoriasis Patients Treated With Secukinumab: A Retrospective Case Series

Journal of the European Academy of Dermatology and Venereology
DermatologyInfectious Diseases
2018English

Real‐World Evidence of Secukinumab in Psoriasis Treatment – A Meta‐Analysis of 43 Studies

Journal of the European Academy of Dermatology and Venereology
DermatologyInfectious Diseases
2020English

Dyshidrotic Eczema in Two Patients on Secukinumab for Plaque Psoriasis: A Case Report

SAGE Open Medical Case Reports
2020English

Magnetic Seizure Therapy: Towards Personalized Seizure Therapy for Major Depression

Personalized Medicine in Psychiatry
2019English

Secukinumab: First IL-17A Antagonist for Plaque Psoriasis

Pharmacy Today
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy